SACITUZUMAB GOVITECAN EFFICACIOUS IN ADDITIONAL CANCERS: UPDATED EFFICACY AND SAFETY RESULTS FROM THE PHASE I/II IMMU-132-02 TRIAL
The phase I/II IMMU-132-01 trial has previously reported efficacious results with the antibody-drug conjugate sacituzumab govitecan (SG) in various advanced epithelial cancers. In an updated analysis of this trial, SG was found to have manageable adverse events comparable to chemotherapy, and showed efficacy in colorectal, endometrial, oesophageal, pancreatic, castration-resistant prostate and small cell lung cancers… Read more
OLAPARIB MAINTENANCE INDUCES A SURVIVAL IMPROVEMENT IN PLATINUM-SENSITIVE OVARIAN CANCER PATIENTS WITH BRCA1/2 MUTATIONS
Olaparib maintenance is licensed in various countries for the treatment of platinum-sensitive relapsed ovarian cancer. The final analysis of the phase III SOLO2 trial reveals that the previously reported benefit in progression-free survival (PFS) obtained from olaparib maintenance in patients with relapsed, platinum-sensitive ovarian cancer harbouring a BRCA1/2 mutations, translates into a clinically meaningful survival benefit… Read more
NON-INFERIOR SURVIVAL OUTCOMES IN HIGH CLINICAL/LOW GENOMIC RISK BREAST CANCER PATIENTS WHO FOREGO CHEMOTHERAPY
The phase III MINDACT trial has previously reported that breast cancer patients with a high clinical risk, but low genomic risk, may forego adjuvant chemotherapy. In an updated analysis with a median follow-up of 8.7 years, this conclusion is reinforced. Furthermore, nodal disease does not appear to influence clinical outcome in these patients. In younger patients, the clinical benefit of adding chemotherapy to endocrine therapy was more pronounced… Read more
CLINICAL FACTORS AND RECENT ANTI-CANCER THERAPIES ASSOCIATED WITH COVID-19 SEVERITY IN CANCER PATIENTS
Cancer patients have a greater risk of mortality from COVID-19 compared to the general population. However, research is still ongoing to identify specific risk factors in these patients associated with COVID-19 prognosis. Recently published data from the COVID-19 and Cancer Consortium indicate that certain clinical features and specific prior anti-cancer treatments are associated with a more severe COVID-19 disease course… Read more
NIVOLUMAB PLUS CABOZANTINIB OUTPERFORMS SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
Results of the phase III CheckMate 9ER trial show that the combination of nivolumab and cabozantinib significantly delays disease progression and prolongs the survival of previously untreated patients with advanced renal cell carcinoma (aRCC) compared to sunitinib. These findings mark nivolumab-cabozantinib as yet another treatment option in this setting… Read more
Top
